Login to Your Account



Other News To Note


Friday, June 17, 2011
NovaBay Pharmaceuticals Inc., of Emeryville, Calif., regained worldwide rights to its topical Aganocide compounds for antibiotic-resistant eye, ear and sinus infections after Alcon Inc., of Huenenberg, Switzerland, terminated the companies' collaboration. NovaBay will receive a $2.97 million termination payment. Alcon completed a proof-of-concept trial of NVC-422 in viral conjunctivitis last fall.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription